Cancer of the ovaries is the fifth leading cause of cancer-related death among women in the United States. An estimated 15,460 women died from the disease in 2011, and almost 22,000 new cases were diagnosed¹. Ovarian cancer is sometimes called the silent killer because many patients are without symptoms until the disease is quite advanced. While there has been some progress in the treatment of ovarian cancer in recent decades, only 10-30% of women diagnosed with advanced (stage III or IV) disease are alive 5 years after diagnosis². New treatment options are therefore critically needed to prolong the lives of women with advanced ovarian cancer.